GMGrégory Michel

Grégory Michel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Grégory Michel has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Pierre Marty

    Université Côte d'Azur, Inserm, C3M, Nice Cedex 3, France; Parasitologie-Mycologie, Centre Hospitalier Universitaire l'Archet, Nice Cedex 3, France

    4 shared publications
  • Bernard Ferrua

    Inserm U1065, Centre Méditerranéen de Médecine Moléculaire, Team "Microbial toxins in host pathogen interactions", Equipe labellisée ligue contre le cancer, Nice, France

    3 shared publications
  • Christelle Pomares

    Université Côte d'Azur, Inserm, C3M, Nice Cedex 3, France; Parasitologie-Mycologie, Centre Hospitalier Universitaire l'Archet, Nice Cedex 3, France

    3 shared publications
  • Emmanuel Lemichez

    Département de Microbiologie, Unité des Toxines Bactériennes, Institut Pasteur, CNRS UMR6047, INSERM U1306, Université Paris Cité, Paris 75015, France

    2 shared publications
  • Patrick Munro

    INSERM U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Bâtiment Universitaire ARCHIMED, 151 Route de Saint Antoine de Ginestière BP, 23194 Nice, France

    2 shared publications
  • Alissa Majoor

    Université Côte d'Azur, Inserm, C3M, Nice Cedex 3, France

    1 shared publication

Latest Publications

  • Leishmania infection: Misdiagnosis as cancer and tumor-promoting potential

    by Aurélie Schwing, Christelle Pomares, Alissa Majoor, Laurent Boyer, Pierre Marty, Grégory Michel


  • Open Access

    Immunoadjuvant Properties of the Rho Activating Factor CNF1 in Prophylactic and Curative Vaccination against Leishmania infantum

    by Grégory Michel, Bernard Ferrua, Patrick Munro, Laurent Boyer, Nassim Mathal, Daniel Gillet, Pierre Marty, Emmanuel Lemichez

    There is a need to develop new effective immunoadjuvants for prophylactic or therapeutic vaccines against intracellular pathogens. The activation of Rho GTPases by bacterial cytotoxic necrotizing factor 1 (CNF1) elicits humoral protective responses against protein antigens. Here, we set out to investigate whether CNF1 activity initiates humoral immunity against co-administered parasite antigens and anti-microbial immune signaling. We report that co-administration of wild-type (WT) CNF1 with Leishmania (L.) promastigote antigens at the nasal mucosa triggered prophylactic and curative vaccine responses against this parasite. Vaccination of the mucosa with promastigote lysate antigens combined with WT CNF1 conferred protection against high inoculum L. infantum infection, which reached 82% in the spleen. Immune parameter analysis by antigen recall indicated robust T-helper (Th)1 polarization of immune memory cells, with high IL-2 and IFN-γ production combined with decreased IL-4 production. Additionally, we explored the curative effect of WT CNF1 on previously infected animals. We observed that PL combined with WT CNF1, but not the inactive C866S mutant CNF1 (mCNF1), induced a 58% decrease in the parasite burden in the spleen.


  • Open Access

    Luciferase-Expressing Leishmania infantum Allows the Monitoring of Amastigote Population Size, In Vivo, Ex Vivo and In Vitro

    by Grégory Michel, Bernard Ferrua, Thierry Lang, Madhavi P. Maddugoda, Patrick Munro, Christelle Pomares, Emmanuel Lemichez, Pierre Marty

    Here we engineered transgenic Leishmania infantum that express luciferase, the objectives being to more easily monitor in real time their establishment either in BALB/c mice—the liver and spleen being mainly studied—or in vitro. Whatever stationary phase L. infantum promastigotes population—wild type or engineered to express luciferase—the parasite burden was similar in the liver and the spleen at day 30 post the intravenous inoculation of BALB/c mice. Imaging of L. infantum hosting BALB/C mice provided sensitivity in the range of 20,000 to 40,000 amastigotes/mg tissue, two tissues—liver and spleen—being monitored. Once sampled and processed ex vivo for their luciferin-dependent bioluminescence the threshold sensitivity was shown to range from 1,000 to 6,000 amastigotes/mg tissue. This model further proved to be valuable for in vivo measurement of the efficiency of drugs such as miltefosine and may, therefore, additionally be used to evaluate vaccine-induced protection. Leishmania infantum/L. chagasi parasites are inoculated in the skin of mammals by sand flies. Though most often these L. infantum-mammal interactions are asymptomatic, they can proceed, in some individuals, to a systemic disease known as visceral leishmaniasis. If left untreated this disease is fatal. The lack of protective or curative vaccines and the limited number of parasite-targeting drugs were incentive to set up experimental conditions that could allow easy monitoring of the fluctuation of the population size of parasites in living laboratory animals. Thus, in the present report, we depict two distinct readout assays that rely on a population of L. infantum we genetically engineered for stably expressing the firefly luciferase gene. These transgenic parasites were either inoculated to BALB/c mice or added to a culture of monocytic cells. Post intravenous inoculation, BALB/c mice were imaged over time, with special attention being given to the liver and the spleen. The sensitivity of this technique ranged from 20,000 to 40,000 parasites/mg of tissue and from 1,000 to 6,000 parasites/mg tissue, for in vivo and ex vivo measurements, respectively. Though preliminary, the data, relying on monocytic cells, are promising for further in vitro screening of small compound libraries.


  • Importance of worldwide asymptomatic carriers of Leishmania infantum (L. chagasi) in human

    by Grégory Michel, Christelle Pomares, Bernard Ferrua, Pierre Marty


    • 1 January 2011
      • Vol. 195  (1) , 181-8

    [Mediterranean visceral leishmaniasis].

    by Pierre Marty, Christelle Pomares, Grégory Michel, Pascal Delaunay, Bernard Ferrua, Eric Rosenthal

    Mediterranean visceral leishmaniasis is a parasitic zoonosis due to Leishmania infantum. The dog is the reservoir species and also the main victim. The vector is the female Phlebotomus sand fly. In the southern Mediterranean region the disease is most frequent in children, whereas in Europe, and particularly in France, it is mostly an opportunistic infection associated with immunosuppression. Frequent asymptomatic carriage has been detected in southern Europe. The classic symptom triad consists of fever, pallor and splenomegaly. Biological signs include low cell blood counts (anemia, leukoneutropenia, and thrombocytopenia) and an inflammatory syndrome. Commercial serologic tests such as those based on immunoblotting are very useful. The gold standard for diagnosis is parasite detection in bone marrow or blood. PCR is useful for therapeutic follow-up. Treatment is currently based on liposomal amphotericin B (AmBisome).